Dr. Chaplin has served as a senior member of management teams for several biopharma companies. His research in the area of vascular disrupting strategies resulted in the identification of Combretastatin A4P (ZYBRESTAT) (fosbretabulin tromethamine), an anti-cancer therapy currently in late stage development. Prior to joining the company in 2000 as chief scientific officer, Dr. Chaplin served as vice president of Oncology for Aventis (now Sanofi), where he led all oncology drug discovery and early clinical development worldwide.
On behalf of OXiGENE's board, chairman Fred Driscoll said, "We are pleased to have a person of Dai's caliber and reputation on our management team to lead the Company and its compounds towards potential commercialization." Mr. Driscoll continued, "Dai's background in anti-cancer drug development, in particular his extensive knowledge of ZYBRESTAT, and his involvement with OXiGENE dating back to 2000 make him a superb choice to lead the Company at this time."
Mr. Driscoll added, "We thank Peter Langecker for his leadership over the past five years during an important and challenging phase of OXiGENE's growth and development. We wish Peter success in his future endeavors."